Literature DB >> 16033854

Time-dependent associations between iron and mortality in hemodialysis patients.

Kamyar Kalantar-Zadeh1, Deborah L Regidor, Charles J McAllister, Beckie Michael, David G Warnock.   

Abstract

The independent association between the indices of iron stores or administered intravenous iron, both of which vary over time, and survival in patients who are on maintenance hemodialysis (MHD) is not clear. It was hypothesized that the observed associations between moderately high levels of three iron markers (serum ferritin, iron, and iron saturation ratio) or administered intravenous iron and all-cause and cardiovascular death is due to the time-varying confounding effect of malnutrition-inflammation-cachexia syndrome (MICS). Time-dependent Cox regression models were examined using prospectively collected data of the 2-yr (July 2001 to June 2003) historical cohort of 58,058 MHD patients from virtually all DaVita dialysis clinics in the United States. After time-dependent and multivariate adjustment for case mix, administered intravenous iron and erythropoietin doses, and available surrogates of MICS, serum ferritin levels between 200 and 1200 ng/ml (reference 100 to 199 ng/ml), serum iron levels between 60 and 120 microg/ml (reference 50 to 59 microg/ml), and iron saturation ratio between 30 and 50% (reference 45 to 50%) were associated with the lowest all-cause and cardiovascular death risks. Compared with those who did not receive intravenous iron, administered intravenous iron up to 400 mg/mo was associated with improved survival, whereas doses >400 mg/mo tended to be associated with higher death rates. The association between serum ferritin levels >800 ng/ml and mortality in MHD patients seems to be due mostly to the confounding effects of MICS. For ascertaining whether the observed associations between moderate doses of administered intravenous iron and improved survival are causal or due to selection bias by indication, clinical trials are warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16033854     DOI: 10.1681/ASN.2005040423

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  84 in total

1.  Serum ferritin predicts prognosis in hemodialysis patients: the Nishinomiya study.

Authors:  Yukiko Hasuike; Hiroshi Nonoguchi; Masanori Tokuyama; Mai Ohue; Takanori Nagai; Mana Yahiro; Masayoshi Nanami; Yoshinaga Otaki; Takeshi Nakanishi
Journal:  Clin Exp Nephrol       Date:  2010-05-14       Impact factor: 2.801

Review 2.  Medical safety in the care of the person with end-stage kidney disease.

Authors:  John V Duronville; Clarissa J Diamantidis
Journal:  Semin Dial       Date:  2018-01-07       Impact factor: 3.455

3.  Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease.

Authors:  Paolo Ferrari; Hemant Kulkarni; Shyam Dheda; Susanne Betti; Colin Harrison; Timothy G St Pierre; John K Olynyk
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

4.  High platelet count as a link between renal cachexia and cardiovascular mortality in end-stage renal disease patients.

Authors:  Miklos Z Molnar; Elani Streja; Csaba P Kovesdy; Matthew J Budoff; Allen R Nissenson; Mahesh Krishnan; Stefan D Anker; Keith C Norris; Gregg C Fonarow; Kamyar Kalantar-Zadeh
Journal:  Am J Clin Nutr       Date:  2011-08-03       Impact factor: 7.045

Review 5.  Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease.

Authors:  Elena Canavesi; Carlo Alfieri; Serena Pelusi; Luca Valenti
Journal:  World J Nephrol       Date:  2012-12-06

Review 6.  Review article: Biomarkers of clinical outcomes in advanced chronic kidney disease.

Authors:  Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nephrology (Carlton)       Date:  2009-06       Impact factor: 2.506

7.  Serum Ferritin Variations and Mortality in Incident Hemodialysis Patients.

Authors:  Taehee Kim; Elani Streja; Melissa Soohoo; Connie M Rhee; Rieko Eriguchi; Tae Woo Kim; Tae Ik Chang; Yoshitsugu Obi; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Am J Nephrol       Date:  2017-07-14       Impact factor: 3.754

8.  Cumulative iron dose and resistance to erythropoietin.

Authors:  A Rosati; C Tetta; J I Merello; I Palomares; R Perez-Garcia; F Maduell; B Canaud; P Aljama Garcia
Journal:  J Nephrol       Date:  2014-08-05       Impact factor: 3.902

Review 9.  The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions.

Authors:  Donald S Silverberg; Dov Wexler; Adrian Iaina; Doron Schwartz
Journal:  Clin Exp Nephrol       Date:  2008-08-01       Impact factor: 2.801

10.  Parenteral iron use: possible contribution to exceeding target hemoglobin in hemodialysis patients.

Authors:  Hassan N Ibrahim; Robert N Foley; Rui Zhang; David T Gilbertson; Allan J Collins
Journal:  Clin J Am Soc Nephrol       Date:  2009-02-11       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.